Thomas Civik - 31 Mar 2025 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Thomas Civik
Issuer symbol
PYXS
Transactions as of
31 Mar 2025
Net transactions value
+$36,239
Form type
4
Filing time
02 Apr 2025, 08:57:37 UTC
Previous filing
20 Jun 2024
Next filing
28 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $36,239 +36,979 $0.9800 36,979 31 Mar 2025 Common Stock 36,979 $0.9800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.